| Title |
Thalidomide for managing cancer cachexia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, April 2012
|
| DOI | 10.1002/14651858.cd008664.pub2 |
| Pubmed ID | |
| Authors |
Joanne Reid, Moyra Mills, Marie M Cantwell, Chris R Cardwell, Liam J Murray, Michael Donnelly |
| Abstract |
Cancer cachexia is a multidimensional syndrome characterised by wasting, loss of weight, loss of appetite, metabolic alterations, fatigue and reduced performance status. A significant number of patients with advanced cancer develop cachexia before death. There is no identified optimum treatment for cancer cachexia. While the exact mechanism of the action of thalidomide is unclear, it is known to have immunomodulatory and anti-inflammatory properties, which are thought to help reduce the weight loss associated with cachexia. Preliminary studies of thalidomide have demonstrated encouraging results. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 33% |
| Scientists | 1 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 259 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Hong Kong | 1 | <1% |
| Ireland | 1 | <1% |
| Canada | 1 | <1% |
| United Kingdom | 1 | <1% |
| Unknown | 253 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 41 | 16% |
| Researcher | 29 | 11% |
| Student > Bachelor | 25 | 10% |
| Student > Ph. D. Student | 22 | 8% |
| Student > Postgraduate | 16 | 6% |
| Other | 52 | 20% |
| Unknown | 74 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 90 | 35% |
| Nursing and Health Professions | 29 | 11% |
| Psychology | 15 | 6% |
| Biochemistry, Genetics and Molecular Biology | 9 | 3% |
| Social Sciences | 7 | 3% |
| Other | 26 | 10% |
| Unknown | 83 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 May 2020.
All research outputs
#7,236,093
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#8,304
of 11,499 outputs
Outputs of similar age
#47,152
of 174,458 outputs
Outputs of similar age from Cochrane database of systematic reviews
#122
of 177 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 174,458 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 177 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.